MLTX · MoonLake Immunotherapeutics · Executive Compensation
Market Cap
$1.02B
Shares
85.11M
Volume · Oct 6
3.05M
Avg daily vol (3M)
1.4M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dr. Jorge Santos da Silva | Chief Executive Officer and Interim Chair of the Board | $4,943,209 |
| Dr. Kristian Reich | Chief Scientific Officer | $4,795,493 |
| Matthias Bodenstedt | Chief Financial Officer | $4,692,576 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Jorge Santos da Silva | Chief Executive Officer | $1,406,038 |
| Dr. Kristian Reich | Chief Scientific Officer | $1,302,939 |
| Matthias Bodenstedt | Chief Financial Officer | $1,032,555 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Kristian Reich | Chief Scientific Officer | $1,230,904 |
| Dr. Jorge Santos da Silva | Chief Executive Officer | $1,198,215 |
| Matthias Bodenstedt | Chief Financial Officer | $891,597 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Matthias Bodenstedt | Chief Financial Officer | $5,632,470 |
| Dr. Kristian Reich | Chief Scientific Officer | $4,565,756 |
| Dr. Jorge Santos da Silva | Chief Executive Officer | $4,477,381 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Spike Loy | Class I Director Nominee | Appointed | 2026-06-09 |
| Spike Loy | Lead Independent Director | Appointed | 2026-02-23 |
| Jorge Santos da Silva | Interim Chair of the Board | Appointed | 2026-02-23 |
| Simon Sturge | member of the Board | Resigned | 2026-02-23 |
| Dr. Kara Lassen | member of the Board | Resigned | 2024-12-18 |